Abstract
Long-term hematopoietic stem cells (LT-HSCs) replenish the innate and adaptive immune compartments throughout life. While significant progress has defined the major transcription factors that regulate lineage specification, the architectural proteins that globally coordinate DNA methylation, histone modification, and changes in gene expression are poorly defined. Provocative new studies establish the chromatin organizer Satb1 as one such global regulator in LT-HSCs. Satb1 is a nuclear organizer that partitions chromatin through the formation of cage-like structures. By integrating epigenetic and transcriptional pathways, Satb1 coordinates LT-HSC division, self-renewal, and lymphoid potential. Unexpected among the assortment of genes under Satb1 control in HSCs are cytokines, a finding that takes on additional importance with the provocative finding that short-term (ST-) HSCs and downstream multipotent progenitors (MPPs) are potent and biologically relevant cytokine secretors during stress-mediated hematopoiesis. Together these studies reveal a new mechanism of fate regulation and an unforeseen functional capability of HSCs.
The molecular mechanisms that regulate long-term hematopoietic stem cell (LT-HSC) quiescence, self-renewal and differentiation are incompletely understood. Major progress has identified key transcriptional and signaling regulators of self-renewal and lympho-myeloid potential (1-3), organized their activity into defined modules (4-7), and resolved how shared transcription factors govern distinct lineage fate programs depending on timing and context of expression (8). However, major questions remain. For example, while the changes in histone marks and DNA methylation that regulate gene suites are increasingly well resolved (9-12), how these epigenetic processes are tandemly coordinated in LT-HSCs is not known. Moreover, the classical model for LT-HSC biology is changing with the realization that hematopoietic stem and progenitor cells (HSPCs) directly sense pathogens through toll-like receptors (TLR), functionally responding with accelerated differentiation, lineage-biased output, and even lineage fate re-direction at the single cell level (13-15). Thus, rather than simply replenishing downstream immune cell subsets, LT-HSCs and their immediate progeny detect pathogen signals actively and respond by selective differentiation. Even more important, a new study shows that TLR activation elicits cytokine secretion by short-term (ST-) HSCs and multipotent progenitors (MPPs), with the magnitude and diversity of cytokine production rivaling that of mature immune cell subsets under the same conditions (16). The revelation of this previously unrecognized paracrine function firmly changes our view of HSCs as passive responders to the depletion of mature immune cell subsets, and instead positions HSCs as central players in directing hematopoietic outcomes in the contexts infection and inflammation.
Epigenetic and transcriptional regulation of HSCs
Blood cell replenishment throughout life depends on two functional features of LT-HSCs: quiescence (i.e., activation status) and fate choice (i.e., the balance between self-renewal and differentiation). During hematopoiesis, self-renewing LT-HSCs give rise sequentially to STHSCs and then MPPs, the last of which has limited, if any, self-renewal potential but retains the ability to produce all blood cell subsets (17, 18). MPPs, in turn, produce lympho-myeloid primed MPPs (LMPPs) that have robust lymphoid and myeloid potential but have lost megakaryocyte and erythroid potentials (19-21). Total LMPPs also contain the rag1+ early lymphoid progenitor (ELP) subset (22). LMPP/ELPs then differentiate to intermediates with select lineage development capabilities. Common lymphoid progenitors (CLPs) produce B cell, natural killer (NK) and dendritic cell (DC) lineages and, with poor efficiency, T cells (23, 24). Reciprocally, early thymic progenitors (ETPs) that transit from bone marrow to thymus have robust T cell potential and retain some NK, DC, and myeloid potential but little B cell activity (25). Granulocyte-macrophage progenitors (GMPs) rapidly produce granulocytes and macrophages (26, 27). Disruption in the balance between self-renewal and differentiation is associated with both hematopoietic failure and leukemic transformation. The dynein-binding protein Lis1, for example, is required for both maintenance of the stem cell pool and for leukemic propagation. Conditional ablation of Lis1 increases the frequency of asymmetric HSC divisions ultimately leading to a striking bloodless phenotype while deletion of Lis1 in human leukemia blocks oncogenic growth (28).
HSCs are marked by high levels of DNA methylation and bivalent histone marks, a chromatin signature thought to reflect developmental genes poised for expression. DNA methylation threshold is clearly important as HSCs from mice with reduced DNA methyltransferase I undergo erythro-myeloid differentiation at the expense of lymphoid development (10). During cell fate specification, bivalent marks at cis regulatory regions are resolved with lineage-appropriate genes gaining the presence of additional activating H3K4me3 modifications and lineage-inappropriate genes repressed by H3K27me3 modifications (12). PU.1, E2A and Ikaros are among the major transcription factors that regulate lineage specification programs. PU.1 is an ETS-related family member, Ikaros is a zinc-finger protein 1 family member, and E2A belongs with the E family of helix-loop-helix proteins. These three transcription factors act to promote the expression of lineage-specific genes and repress alternate fates, with transcriptional activity exhibiting striking dose dependence. Disrupted expression of any single factor due, for example, to genetic haploinsufficiency is mechanistically associated with malignancy (29-31). Significant progress has established the coordinated action of PU.1, E2A and Ikaros within defined, interacting networks.
PU.1 has a major role in HSC lineage potential with high, intermediate, and low levels of PU.1 promoting myeloid, lymphoid, and erythroid fate, respectively (32, 33). Concordantly, PU.1-deficient mice die embryonically due to a gross failure of hematopoiesis (34). At high doses, PU.1 drives expression of major myeloid-associated genes including the c-fms cytokine receptor and FcRγII/III, an outcome that is reinforced by a feed forward mechanism involving the activities of Egr and Nab2 which coordinate macrophage versus neutrophil output (7). PU.1 activity needs to be actively restrained to foster lymphopoiesis, and one requisite modulating influence is exerted by the transcriptional regulator Gfi1 (33, 35). Gfi1 physically displaces PU.1 from autoregulatory elements, thereby alleviating PU.1 auto-amplification (7). At these intermediate levels, PU.1 along with Ikaros drives major lymphoid-associated genes such as the Flt3 cytokine receptor (36). Consistent with the role of Gfi1 in restraining PU.1 activity, Gfi1-deficient animals have increased myeloid precursors and complementary reductions in B and T cell development. Mechanistically, PU.1 mediates these diverse lineage-specific effects through both nucleosome remodeling and H3K4me1 histone methylation at distinct target genes, depending on whether PU.1 is activated in the context of myeloid-associated (e.g., Gfi1 or C/EBPβ) or lymphoid-associated (e.g., E2A) co-factors, respectively (37).
E2A and Ikaros regulate HSC self-renewal as well as promote lymphoid fate decisions (38-43). E2A preserves HSC self-renewal potential in part through directly activating the p21 (CIP1/WAF1) cell cycle inhibitor (42, 43). Mice deficient in the E2A isoform E47 exhibit decreased p21, a loss of G0 quiescence, and hyperproliferation that ultimately leads to HSC exhaustion (43, 44). Mice bearing a point mutation in Ikaros have a diminished LT-HSC compartment that fails to expand in response to supportive Notch signals (45). Both E2A-deficient and Ikaros-deficient mice exhibit a complete block in B cell development due to a paucity of LMPPs, and aberrant T cell development accompanied by spontaneous T cell leukemias (38, 46). E2A along with PU.1 regulates expression of IL7R, a key cytokine receptor in lymphoid formation (47). Additionally, Ikaros directly engages Gfi1 regulatory targets thereby reinforcing Gfi1-mediated restraint of PU.1 levels to within the lymphoid-supportive range (7). E2A remains important during B and T cell commitment. Within B cell precursors, E2A activates EBF and Pax5 along with FOXO1 to promote rag gene expression, V(D)J recombination, and formation of the B cell receptor (5, 6, 48, 49). E2A occupancy is associated with increased H3K4 monomethylation across a spectrum of lineage-specific cis regulatory regions (5). Within T cell precursors, E2A signals are delivered in the context of Notch1 which has the effect of simultaneously antagonizing the B and myeloid fates while activating T cell specific genes including Gata3, TCF1, and Bcl11b (4, 8). Conversely, E protein activity needs to be restrained for the formation of innate lymphoid cells (ILCs), including NK cells and the cytokine-producing ILC subsets (50).
Together, these findings establish the regulatory circuitry that guides HSC to the lymphoid versus myeloid lineage fates. What remains unknown is how the epigenetic and transcriptional pathways are themselves regulated.
The global chromatin organizer Satb1 in hematopoiesis
Two new publications identify the special AT-rich binding protein 1 organizer (Satb1) as coordinating HSC activity at the levels of DNA methylation, histone modification and gene transcription. The global chromatin organizer Satb1 was first cloned two decades ago based on the ability to bind to the matrix attachment region (MAR) 3′ of the immunoglobulin heavy chain (IgH) locus (51). The nominal allusion to special binding refers to the ability of Satb1 to preferentially recognize double-stranded DNA in base unpairing regions (BURs), stretches of DNA that become unpaired when subject to negative superhelical strain. The tendency to unpair, or unwind, is observed in DNA sequences flanking the IgH enhancer and intronic kappa enhancer (iEκ) among other genes, augmenting lineage-specific expression (51-53). The geometry of Satb1 nuclear distribution is striking (Figure 1A, upper). Satb1 has a dense cage-like distribution that folds chromatin into organized domains, an effective visual indicator for understanding Satb1 activity. Similar structures are apparent in mouse and man (54, 55). Satb1 effectively serves as a physical platform for co-recruiting target DNA sequences and chromatin-modifying enzymes (54). The functional implication is that Satb1 links nuclear architecture, chromatin structure, and domain organization of DNA sequences.
Figure 1. HSCs: a new chromatin organizer and the revelation of a previously unrecognized paracrine function.
A) Satb1 forms a three dimensional cage-like structure that organizes chromatin. Upper: Pseudo-color image of Satb1 (gold-orange) and DAPI/DNA (light blue) in thymocytes. Lower: Satb1 regulates HSC self-renewal and lymphoid versus myeloid fate through global coordination of DNA cytosine methylation, histone marking, and gene expression. Unexpectedly, Satb1 appears to act in advance of, or in parallel with, the canonical transcription factors associated with lymphoid versus myeloid fate choice. B) Infection stress drives biologically relevant cytokine production by HSPCs. ST-HSCs and MPPs produce cytokines following engagement of plasma membrane TLR2 or TLR4. Cytokine production is NFκB-dependent. Satb1 regulates cytokine gene transcription in HSCs under non-infectious circumstances, and whether Satb1 plays this same role during infection stress remains to be examined. In vivo, HSPC-derived IL-6 acts in a paracrine manner to augment myeloid recovery during neutropenia. Among total HSPCs, two patterns of cytokine emerge: a myeloid profile (IL-6, TNFα, IL-12, GM-CSF) and a lymphoid profile (IL-2, IL-4, IL-10, IFNγ). Upper left image printed with permission from Dr. Terumi Kohwi-Shigematsu, Lawrence Berkeley National Laboratory.
Due to particularly high expression in thymus, the biological function of Satb1 was first extensively characterized in T cell precursors. Satb1-deficient mice exhibit a disordered pattern of gene expression in thymocytes, including dramatic changes in the expression of the cytokine receptor chains IL7R, IL2Rα and γc, effectively disrupting T lineage fate specification (56). At the IL2Rα promoter, for example, Satb1 normally restrains expression to physiologic levels by recruiting the NURD chromatin remodeling complex along with the ISWI and ASF1 nucleosome mobilization complexes leading to histone H4 hypoacetylation and long-range (>7kb) nucleosome repositioning (57). Consequently, Satb1-deficient progenitors have a partial block at DN3, at the DP to SP transition, and a bizarre accumulation of peripheral T cells marked by diffuse rather than discrete CD4+ or CD8+ flow cytometry profiles. Beyond thymocytes, Satb1 has broad activity across hematopoietic and non-hematopoietic lineages in both mouse and man including roles in each B cell formation (56), globin expression in erythroid progenitors (58), Wnt/β-catenin mediated Th2 differentiation (55), and fate determination in embryonic stem cells (59).
Satb1 regulates LT-HSC self-renewal and lineage potential through the global coordination of DNA methylation, histone activation, and gene transcription
Provocative new studies by Will et al. (60) and Satoh et al. (61) reveal a new mechanism of regulation of HSC fate. Satb1 directs not only the major opposing functions of self-renewal versus differentiation, but also lymphoid potential.
The goal propelling Will et al. (60) was to distill how quiescence, division, and lineage commitment are coordinated in HSCs. To avoid high perinatal lethality, the authors used reconstitution chimeras in which Satb1-deficient progenitors were engrafted into wild type hosts. Post-transplantation, Satb1-deficient HSCs (CD150+LSK, lineage-negative, Sca-1+, c-kit+) exhibited a loss of G0 quiescence and poor performance in serial competitive serial transplantation assays, indicating a loss of self-renewal potential. At the single cell level, Satb1-deficient HSCs but not MPPs had enhanced myeloid potential, suggesting that Satb1 restrains differentiation specifically in the former hematopoietic subset. Moreover, Satb1-deficient HSCs also exhibited more symmetric differentiation divisions and fewer symmetric self-renewal divisions due in part to increased levels of the cell polarity factor Numb (3). Satb1 binding to promoter regions of Numb and another regulator of self-renewal, Myc, in an HSC cell line decreased the abundance of permissive H3K4me3 histone marks. Genome-wide assays revealed a pattern of DNA cytosine methylation in Satb1-deficient HSCs resembling that of wild type MPPs, a cellular state poised for differentiation. In the absence of Satb1, >50 genes were identified with paired changes in both transcription and flanking methylation. Genes with altered expression include major regulators of cell cycling (Rbbp9, Kdm3a, Chaf1a, Bgn), cell organization and polarity (lptr1, Tnik) as well as a pleiotropic regulator (Myc). Thus, within HSCs, Satb1 is the first well-characterized chromatin remodeler that coordinates the expression of genes at the levels of transcript expression, histone modification and DNA methylation (Figure 1A, lower).
Using an independent approach Satoh et al. (61) sought to identify initiators of lymphoid potential that may act in advance of, or in parallel with, defined transcription factors. The authors identified Satb1 in a comparative array between rag1− HSCs (self-renewing, multipotent) and rag1+ ELPs (non-renewing, high lymphoid potential, poor erythro-myeloid potential). The detection of Satb1 along with a cohort of lymphoid-specific genes suggested that lymphoid lineage fate specification may be initiated before the ELP stage. Sorted Satb1-deficient HSCs had poor lymphoid differentiation in defined in vitro cultures or following in vivo transfer to wild type hosts, while myeloid potential was comparable to controls. Reciprocally, ectopic expression of Satb1 in HSCs conferred enhanced B and T cell output, in terms of both numbers and kinetics. These finding suggest that Satb1 regulates lymphoid lineage decisions in single HSCs. Moreover, enforced Satb1 also significantly restored the B lymphoid potential of HSCs from two year old mice, an age at which lymphoid potential is severely crippled. Although overexpression of Satb1 in this model did not cause oncogenic transformation, single nucleotide polymorphisms (SNPs) in a Satb1 binding site in a PU.1 distal enhancer are mechanistically linked to acute myeloid leukemia (AML) (31, 62).
The molecular basis for Satb1-mediated regulation of lymphoid-potential is both a little perplexing and potentially exciting. One possibility is that Satb1 augments expression of lymphoid-specific transcription factors (i.e., Ikaros, E2A, EBF, Notch1) while restraining myeloid-specific factors (i.e., PU.1). An alternative but not mutually exclusive possibility is that Satb1 changes the developmental context in which these transcriptional programs exert activity, thereby influencing fate choice. Comparative microarray between wild type and Satb1-overexpressing HSCs (flk2− LSK) reveals that lymphoid potential appears to be enhanced without detectable change in the expression of the canonical transcriptional regulators PU.1, Ikaros, E2A, Notch1 or C/EBPα (61). Rather, other lymphoid-associated transcription factors and genes (Sp4, Maf, Fos, Id3, CD86, rag1) are upregulated and a major myeloid associated factor (Csf3r) is downregulated following Satb1 transduction. It is clear that the biological impact of transcription factors depends on exact the cellular and temporal context in which they are expressed. For example, a shared set of E proteins drives different fate decisions during B versus T cell development due in part to the distinct transcriptional and signaling environment in which they operate (8). Unexpectedly, an unforeseen third possibility arises. Transcripts for stem cell factor (SCF) and IL-7 – cytokine genes traditionally associated with stromal cells – are also upregulated in Satb1-transduced HSCs (61). HSCs are not traditionally recognized for their cytokine secretion potential, and protein levels of these cytokines were not examined in these experiments. However, a major new study reveals the potential of HSC subsets and downstream MPPs to elaborate large amounts of cytokines that functionally influence hematopoiesis (16), immediately raising the potential impact of these striking observations.
LT-HSCs directly respond to danger, and potently secrete cytokines that influence hematopoiesis
LTHSCs and their downstream progeny express TLRs and can respond directly to pathogen. Following TLR stimulation, murine HSCs (14, 15) as well as human HSCs (63-67) proliferate and preferentially undergo myeloid-specific differentiation. Direct sensing of TLR ligand is thought to enable HSCs to immediately replenish innate immune cells that are rapidly depleted during infection, so-called demand adapted hematopoiesis (68). Indeed, circulating HSCs that have exited the marrow undergo rapid myeloid differentiation in response to TLR4 ligand, suggesting that both bone marrow resident HSCs and migratory HSCs directly respond to TLR danger signals (14). The functional significance of TLR-sensing by HSCs and HSPCs is just beginning to be explored.
Using a powerful microfluidic-based proteomic platform to measure cytokine production by single cells, Zhao et al. (16) show that HSPCs secrete large amounts of cytokines following TLR2 and TLR4 stimulation (Figure 1B). At the single cell level, 50-70% of each ST-HSCs and MPPs produced cytokines including IL-6, TNFα, GM-CSF and IL-1β. Moreover, the magnitude and breadth of cytokine production exceeded that of splenic myeloid and lymphoid cells under parallel conditions. Cytokine production depends on NFκB, a transcription factor central to inflammation in multiple immune cell types. LT-HSC had relatively lesser capabilities for cytokine production under these in vitro on-chip conditions, with 0.8% or 7% of single HSCs were identified as cytokine producers using the CD150+CD48− LSK or flk2−CD34− LSK phenotypic definitions, respectively. SCF and IL-7, the cytokines detected following enforced expression of Satb1 in HSCs (61) were not among the 12 cytokines assayed in the microchip panel, and remain to be further investigated. The authors hypothesize that HSPC-produced cytokines may influence the developmental trajectory of neighboring HSPCs in bone marrow niches. This functional property of HSPCs may be advantageous in the context of infection, as responses to locally-sourced cytokine could circumvent the lag time needed to accrue long-distance signals from systemically-derived cytokines or from migratory white blood cells activated at distal effector sites (16, 68) Within total HSPCs, LT-HSCs bear receptors for IL-6, TNF and IFNγ (69-72)while total LSKs additionally express the receptor for GM-CSF (73). Studies with neutralizing antibodies and gene knockout mice prompted the authors to focus on IL-6. In vivo, under a neutropenic regime, HSPC-derived cytokines are shown to enhance myelopoiesis in an IL-6-dependent manner. The revelation of HPSCs as potent cytokine producers raises major new questions about the biological contribution of this pathway to hematopoietic activity under homeostasis and stress. The functional impact of HSPCs-derived cytokines is likely to be highest when downstream cytokine-producing cells are depleted due to infection or inflammation.
Conclusions
Together, these findings establish the epigenetic modifier Satb1 as a major participant in HSC self-renewal and lineage potential, and reveal a new function of ST-HSCs and MPPs as biologically relevant cytokine secretors. Correlative evidence additionally connects Satb1 to the regulation of cytokine gene transcription in LT-HSCs, a finding that is poised for further exploration. These new and unexpected discoveries raise several major questions. First, how is Satb1 itself regulated? At a biochemical level, Satb1 is modified by phosphorylation and acetylation (74, 75), and is susceptible to caspase-mediated cleavage (76). However, little else is known about the pathways that govern expression. Satb1 transcript is reduced in Ikaros-deficient HSCs (77), and whether this regulation is direct or indirect awaits investigation. Likewise, other pathways that influence the developmental-stage specific expression of Satb1 remain to be resolved. Second, unsupervised clustering identified two major cytokine clusters, a lymphoid-associated profile and a myeloid-associated profile (16), raising the prospect that HSPC subsets may contribute to the functional heterogeneity of distinct bone marrow niches (78). Barcoding technology, recently used to trace the developmental fate of single LMPPs in vivo (79), may be similarly useful for tracking the functional capability of single HSPCs in terms of cytokine potential, lineage potential, and possible relationships between the two. Finally, the discovery of HSCs and MPPs as biologically relevant cytokine producers fundamentally changes our understanding of hematopoiesis. HSPCs are much more versatile than previously appreciated, with the ability to both respond to danger signals and to direct hematopoietic outcomes in a paracrine manner. HSPCs have long been known to circulate through blood and lymph raising the possibility of TLR-directed hematopoiesis at localized sites of infection (14). Future studies are likely to reveal important contributions of circulating HSPCs not only in serving to locally replenish immune cells consumed by infection but also in coordinating TLR ligand-specific hematopoiesis.
Acknowledgements
The author thanks Dr. Christine Milcarek, Dr. Louise D’Cruz, and members of the Borghesi and Milcarek labs for thoughtful discussions.
References
- 1.Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, Morgan K, Tam W, Paktinat M, Okabe R, Gozo M, Einhorn W, Lane SW, Scholl C, Frohling S, Fleming M, Ebert BL, Gilliland DG, Jaenisch R, Daley GQ. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010;16:903–908. doi: 10.1038/nm.2187. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Laslo P, Spooner CJ, Warmflash A, Lancki DW, Lee HJ, Sciammas R, Gantner BN, Dinner AR, Singh H. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell. 2006;126:755–766. doi: 10.1016/j.cell.2006.06.052. [DOI] [PubMed] [Google Scholar]
- 3.Wu M, Kwon HY, Rattis F, Blum J, Zhao C, Ashkenazi R, Jackson TL, Gaiano N, Oliver T, Reya T. Imaging hematopoietic precursor division in real time. Cell Stem Cell. 2007;1:541–554. doi: 10.1016/j.stem.2007.08.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Georgescu C, Longabaugh WJ, Scripture-Adams DD, David-Fung ES, Yui MA, Zarnegar MA, Bolouri H, Rothenberg EV. A gene regulatory network armature for T lymphocyte specification. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:20100–20105. doi: 10.1073/pnas.0806501105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Lin YC, Benner C, Mansson R, Heinz S, Miyazaki K, Miyazaki M, Chandra V, Bossen C, Glass CK, Murre C. Global changes in the nuclear positioning of genes and intra- and interdomain genomic interactions that orchestrate B cell fate. Nat Immunol. 2012;13:1196–1204. doi: 10.1038/ni.2432. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Mansson R, Welinder E, Ahsberg J, Lin YC, Benner C, Glass CK, Lucas JS, Sigvardsson M, Murre C. Positive intergenic feedback circuitry, involving EBF1 and FOXO1, orchestrates B-cell fate. Proc Natl Acad Sci U S A. 2012;109:21028–21033. doi: 10.1073/pnas.1211427109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Spooner CJ, Cheng JX, Pujadas E, Laslo P, Singh H. A recurrent network involving the transcription factors PU.1 and Gfi1 orchestrates innate and adaptive immune cell fates. Immunity. 2009;31:576–586. doi: 10.1016/j.immuni.2009.07.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Rothenberg EV. Transcriptional control of early T and B cell developmental choices. Annu Rev Immunol. 2014;32:283–321. doi: 10.1146/annurev-immunol-032712-100024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL, Lander ES. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006;125:315–326. doi: 10.1016/j.cell.2006.02.041. [DOI] [PubMed] [Google Scholar]
- 10.Broske AM, Vockentanz L, Kharazi S, Huska MR, Mancini E, Scheller M, Kuhl C, Enns A, Prinz M, Jaenisch R, Nerlov C, Leutz A, Andrade-Navarro MA, Jacobsen SE, Rosenbauer F. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet. 2009;41:1207–1215. doi: 10.1038/ng.463. [DOI] [PubMed] [Google Scholar]
- 11.Spivakov M, Fisher AG. Epigenetic signatures of stem-cell identity. Nat Rev Genet. 2007;8:263–271. doi: 10.1038/nrg2046. [DOI] [PubMed] [Google Scholar]
- 12.Weishaupt H, Sigvardsson M, Attema JL. Epigenetic chromatin states uniquely define the developmental plasticity of murine hematopoietic stem cells. Blood. 2010;115:247–256. doi: 10.1182/blood-2009-07-235176. [DOI] [PubMed] [Google Scholar]
- 13.Esplin BL, Shimazu T, Welner RS, Garrett KP, Nie L, Zhang Q, Humphrey MB, Yang Q, Borghesi LA, Kincade PW. Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol. 2011;186:5367–5375. doi: 10.4049/jimmunol.1003438. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Massberg S, Schaerli P, Knezevic-Maramica I, Kollnberger M, Tubo N, Moseman EA, Huff IV, Junt T, Wagers AJ, Mazo IB, von Andrian UH. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell. 2007;131:994–1008. doi: 10.1016/j.cell.2007.09.047. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Nagai Y, Garrett KP, Ohta S, Bahrun U, Kouro T, Akira S, Takatsu K, Kincade PW. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity. 2006;24:801–812. doi: 10.1016/j.immuni.2006.04.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Zhao JL, Ma C, O’Connell RM, Mehta A, Diloreto R, Heath JR, Baltimore D. Conversion of Danger Signals into Cytokine Signals by Hematopoietic Stem and Progenitor Cells for Regulation of Stress-Induced Hematopoiesis. Cell Stem Cell. 2014 doi: 10.1016/j.stem.2014.01.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science. 2011;333:218–221. doi: 10.1126/science.1201219. [DOI] [PubMed] [Google Scholar]
- 18.Yamamoto R, Morita Y, Ooehara J, Hamanaka S, Onodera M, Rudolph KL, Ema H, Nakauchi H. Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. Cell. 2013;154:1112–1126. doi: 10.1016/j.cell.2013.08.007. [DOI] [PubMed] [Google Scholar]
- 19.Adolfsson J, Mansson R, Buza-Vidas N, Hultquist A, Liuba K, Jensen CT, Bryder D, Yang L, Borge OJ, Thoren LA, Anderson K, Sitnicka E, Sasaki Y, Sigvardsson M, Jacobsen SE. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell. 2005;121:295–306. doi: 10.1016/j.cell.2005.02.013. [DOI] [PubMed] [Google Scholar]
- 20.Forsberg EC, Serwold T, Kogan S, Weissman IL, Passegue E. New evidence supporting megakaryocyte-erythrocyte potential of flk2/flt3+ multipotent hematopoietic progenitors. Cell. 2006;126:415–426. doi: 10.1016/j.cell.2006.06.037. [DOI] [PubMed] [Google Scholar]
- 21.Kohn LA, Hao QL, Sasidharan R, Parekh C, Ge S, Zhu Y, Mikkola HK, Crooks GM. Lymphoid priming in human bone marrow begins before expression of CD10 with upregulation of L-selectin. Nat Immunol. 2012;13:963–971. doi: 10.1038/ni.2405. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Igarashi H, Gregory SC, Yokota T, Sakaguchi N, Kincade PW. Transcription from the RAG1 locus marks the earliest lymphocyte progenitors in bone marrow. Immunity. 2002;17:117–130. doi: 10.1016/s1074-7613(02)00366-7. [DOI] [PubMed] [Google Scholar]
- 23.Kondo M, Weissman IL, Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell. 1997;91:661–672. doi: 10.1016/s0092-8674(00)80453-5. [DOI] [PubMed] [Google Scholar]
- 24.Mansson R, Zandi S, Welinder E, Tsapogas P, Sakaguchi N, Bryder D, Sigvardsson M. Single-cell analysis of the common lymphoid progenitor compartment reveals functional and molecular heterogeneity. Blood. 2010;115:2601–2609. doi: 10.1182/blood-2009-08-236398. [DOI] [PubMed] [Google Scholar]
- 25.Bell JJ, Bhandoola A. The earliest thymic progenitors for T cells possess myeloid lineage potential. Nature. 2008;452:764–767. doi: 10.1038/nature06840. [DOI] [PubMed] [Google Scholar]
- 26.Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 2000;404:193–197. doi: 10.1038/35004599. [DOI] [PubMed] [Google Scholar]
- 27.Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A. 2002;99:11872–11877. doi: 10.1073/pnas.172384399. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Zimdahl B, Ito T, Blevins A, Bajaj J, Konuma T, Weeks J, Koechlein CS, Kwon HY, Arami O, Rizzieri D, Broome HE, Chuah C, Oehler VG, Sasik R, Hardiman G, Reya T. Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia. Nature genetics. 2014;46:245–252. doi: 10.1038/ng.2889. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Mathas S, Janz M, Hummel F, Hummel M, Wollert-Wulf B, Lusatis S, Anagnostopoulos I, Lietz A, Sigvardsson M, Jundt F, Johrens K, Bommert K, Stein H, Dorken B. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol. 2006;7:207–215. doi: 10.1038/ni1285. [DOI] [PubMed] [Google Scholar]
- 30.Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X, Pui CH, Relling MV, Evans WE, Shurtleff SA, Downing JR. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758–764. doi: 10.1038/nature05690. [DOI] [PubMed] [Google Scholar]
- 31.Rosenbauer F, Wagner K, Kutok JL, Iwasaki H, Le Beau MM, Okuno Y, Akashi K, Fiering S, Tenen DG. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet. 2004;36:624–630. doi: 10.1038/ng1361. [DOI] [PubMed] [Google Scholar]
- 32.Back J, Dierich A, Bronn C, Kastner P, Chan S. PU.1 determines the self-renewal capacity of erythroid progenitor cells. Blood. 2004;103:3615–3623. doi: 10.1182/blood-2003-11-4089. [DOI] [PubMed] [Google Scholar]
- 33.DeKoter RP, Singh H. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science. 2000;288:1439–1441. doi: 10.1126/science.288.5470.1439. [DOI] [PubMed] [Google Scholar]
- 34.Kim HG, de Guzman CG, Swindle CS, Cotta CV, Gartland L, Scott EW, Klug CA. The ETS family transcription factor PU.1 is necessary for the maintenance of fetal liver hematopoietic stem cells. Blood. 2004;104:3894–3900. doi: 10.1182/blood-2002-08-2425. [DOI] [PubMed] [Google Scholar]
- 35.Arinobu Y, Mizuno S, Chong Y, Shigematsu H, Iino T, Iwasaki H, Graf T, Mayfield R, Chan S, Kastner P, Akashi K. Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages. Cell Stem Cell. 2007;1:416–427. doi: 10.1016/j.stem.2007.07.004. [DOI] [PubMed] [Google Scholar]
- 36.Medina KL, Pongubala JM, Reddy KL, Lancki DW, Dekoter R, Kieslinger M, Grosschedl R, Singh H. Assembling a gene regulatory network for specification of the B cell fate. Developmental cell. 2004;7:607–617. doi: 10.1016/j.devcel.2004.08.006. [DOI] [PubMed] [Google Scholar]
- 37.Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38:576–589. doi: 10.1016/j.molcel.2010.05.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Dias S, Mansson R, Gurbuxani S, Sigvardsson M, Kee BL. E2A proteins promote development of lymphoid-primed multipotent progenitors. Immunity. 2008;29:217–227. doi: 10.1016/j.immuni.2008.05.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Georgopoulos K, Bigby M, Wang JH, Molnar A, Wu P, Winandy S, Sharpe A. The Ikaros gene is required for the development of all lymphoid lineages. Cell. 1994;79:143–156. doi: 10.1016/0092-8674(94)90407-3. [DOI] [PubMed] [Google Scholar]
- 40.Semerad CL, Mercer EM, Inlay MA, Weissman IL, Murre C. E2A proteins maintain the hematopoietic stem cell pool and promote the maturation of myelolymphoid and myeloerythroid progenitors. Proc Natl Acad Sci U S A. 2009;106:1930–1935. doi: 10.1073/pnas.0808866106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.van Galen P, Kreso A, Wienholds E, Laurenti E, Eppert K, Lechman ER, Mbong N, Hermans K, Dobson S, April C, Fan JB, Dick JE. Reduced lymphoid lineage priming promotes human hematopoietic stem cell expansion. Cell Stem Cell. 2014;14:94–106. doi: 10.1016/j.stem.2013.11.021. [DOI] [PubMed] [Google Scholar]
- 42.Yang Q, Esplin B, Borghesi L. E47 regulates hematopoietic stem cell proliferation and energetics but not myeloid lineage restriction. Blood. 2011;117:3529–3538. doi: 10.1182/blood-2010-07-297689. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Yang Q, Kardava L, St Leger A, Martincic K, Varnum-Finney B, Bernstein ID, Milcarek C, Borghesi L. E47 controls the developmental integrity and cell cycle quiescence of multipotential hematopoietic progenitors. J Immunol. 2008;181:5885–5894. doi: 10.4049/jimmunol.181.9.5885. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Santos PM, Ding Y, Borghesi L. Cell-intrinsic in vivo requirement for the E47-p21 pathway in long-term hematopoietic stem cells. J Immunol. 2014;192:160–168. doi: 10.4049/jimmunol.1302502. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Papathanasiou P, Attema JL, Karsunky H, Hosen N, Sontani Y, Hoyne GF, Tunningley R, Smale ST, Weissman IL. Self-renewal of the long-term reconstituting subset of hematopoietic stem cells is regulated by Ikaros. Stem Cells. 2009;27:3082–3092. doi: 10.1002/stem.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Winandy S, Wu P, Georgopoulos K. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell. 1995;83:289–299. doi: 10.1016/0092-8674(95)90170-1. [DOI] [PubMed] [Google Scholar]
- 47.DeKoter RP, Lee HJ, Singh H. PU.1 regulates expression of the interleukin-7 receptor in lymphoid progenitors. Immunity. 2002;16:297–309. doi: 10.1016/s1074-7613(02)00269-8. [DOI] [PubMed] [Google Scholar]
- 48.Borghesi L, Aites J, Nelson S, Lefterov P, James P, Gerstein R. E47 is required for V(D)J recombinase activity in common lymphoid progenitors. J Exp Med. 2005;202:1669–1677. doi: 10.1084/jem.20051190. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Treiber T, Mandel EM, Pott S, Gyory I, Firner S, Liu ET, Grosschedl R. Early B cell factor 1 regulates B cell gene networks by activation, repression, and transcription- independent poising of chromatin. Immunity. 2010;32:714–725. doi: 10.1016/j.immuni.2010.04.013. [DOI] [PubMed] [Google Scholar]
- 50.Boos MD, Yokota Y, Eberl G, Kee BL. Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2-mediated suppression of E protein activity. J Exp Med. 2007;204:1119–1130. doi: 10.1084/jem.20061959. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Dickinson LA, Joh T, Kohwi Y, Kohwi-Shigematsu T. A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell. 1992;70:631–645. doi: 10.1016/0092-8674(92)90432-c. [DOI] [PubMed] [Google Scholar]
- 52.Dickinson LA, Dickinson CD, Kohwi-Shigematsu T. An atypical homeodomain in SATB1 promotes specific recognition of the key structural element in a matrix attachment region. J Biol Chem. 1997;272:11463–11470. doi: 10.1074/jbc.272.17.11463. [DOI] [PubMed] [Google Scholar]
- 53.Kirillov A, Kistler B, Mostoslavsky R, Cedar H, Wirth T, Bergman Y. A role for nuclear NF-kappaB in B-cell-specific demethylation of the Igkappa locus. Nat Genet. 1996;13:435–441. doi: 10.1038/ng0895-435. [DOI] [PubMed] [Google Scholar]
- 54.Cai S, Han HJ, Kohwi-Shigematsu T. Tissue-specific nuclear architecture and gene expression regulated by SATB1. Nat Genet. 2003;34:42–51. doi: 10.1038/ng1146. [DOI] [PubMed] [Google Scholar]
- 55.Notani D, Gottimukkala KP, Jayani RS, Limaye AS, Damle MV, Mehta S, Purbey PK, Joseph J, Galande S. Global regulator SATB1 recruits beta-catenin and regulates T(H)2 differentiation in Wnt-dependent manner. PLoS Biol. 2010;8:e1000296. doi: 10.1371/journal.pbio.1000296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, Kohwi-Shigematsu T. The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev. 2000;14:521–535. [PMC free article] [PubMed] [Google Scholar]
- 57.Yasui D, Miyano M, Cai S, Varga-Weisz P, Kohwi-Shigematsu T. SATB1 targets chromatin remodelling to regulate genes over long distances. Nature. 2002;419:641–645. doi: 10.1038/nature01084. [DOI] [PubMed] [Google Scholar]
- 58.Wen J, Huang S, Rogers H, Dickinson LA, Kohwi-Shigematsu T, Noguchi CT. SATB1 family protein expressed during early erythroid differentiation modifies globin gene expression. Blood. 2005;105:3330–3339. doi: 10.1182/blood-2004-08-2988. [DOI] [PubMed] [Google Scholar]
- 59.Savarese F, Davila A, Nechanitzky R, De La Rosa-Velazquez I, Pereira CF, Engelke R, Takahashi K, Jenuwein T, Kohwi-Shigematsu T, Fisher AG, Grosschedl R. Satb1 and Satb2 regulate embryonic stem cell differentiation and Nanog expression. Genes Dev. 2009;23:2625–2638. doi: 10.1101/gad.1815709. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD, Verma A, Figueroa ME, Melnick A, Roth M, Steidl U. Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. Nat Immunol. 2013;14:437–445. doi: 10.1038/ni.2572. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Satoh Y, Yokota T, Sudo T, Kondo M, Lai A, Kincade PW, Kouro T, Iida R, Kokame K, Miyata T, Habuchi Y, Matsui K, Tanaka H, Matsumura I, Oritani K, Kohwi-Shigematsu T, Kanakura Y. The Satb1 protein directs hematopoietic stem cell differentiation toward lymphoid lineages. Immunity. 2013;38:1105–1115. doi: 10.1016/j.immuni.2013.05.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Rosenbauer F, Owens BM, Yu L, Tumang JR, Steidl U, Kutok JL, Clayton LK, Wagner K, Scheller M, Iwasaki H, Liu C, Hackanson B, Akashi K, Leutz A, Rothstein TL, Plass C, Tenen DG. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet. 2006;38:27–37. doi: 10.1038/ng1679. [DOI] [PubMed] [Google Scholar]
- 63.De Luca K, Frances-Duvert V, Asensio MJ, Ihsani R, Debien E, Taillardet M, Verhoeyen E, Bella C, Lantheaume S, Genestier L, Defrance T. The TLR1/2 agonist PAM(3)CSK(4) instructs commitment of human hematopoietic stem cells to a myeloid cell fate. Leukemia. 2009;23:2063–2074. doi: 10.1038/leu.2009.155. [DOI] [PubMed] [Google Scholar]
- 64.Reece P, Thanendran A, Crawford L, Tulic MK, Thabane L, Prescott SL, Sehmi R, Denburg JA. Maternal allergy modulates cord blood hematopoietic progenitor Toll-like receptor expression and function. J Allergy Clin Immunol. 2011;127:447–453. doi: 10.1016/j.jaci.2010.11.006. [DOI] [PubMed] [Google Scholar]
- 65.Sioud M, Floisand Y. TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80/86+ DC capable of inducing a Th1-type response. Eur J Immunol. 2007;37:2834–2846. doi: 10.1002/eji.200737112. [DOI] [PubMed] [Google Scholar]
- 66.Sioud M, Floisand Y. NOD2/CARD15 on bone marrow CD34+ hematopoietic cells mediates induction of cytokines and cell differentiation. J Leukoc Biol. 2009;85:939–946. doi: 10.1189/jlb.1008650. [DOI] [PubMed] [Google Scholar]
- 67.Sioud M, Floisand Y, Forfang L, Lund-Johansen F. Signaling through toll-like receptor 7/8 induces the differentiation of human bone marrow CD34+ progenitor cells along the myeloid lineage. J Mol Biol. 2006;364:945–954. doi: 10.1016/j.jmb.2006.09.054. [DOI] [PubMed] [Google Scholar]
- 68.Takizawa H, Boettcher S, Manz MG. Demand-adapted regulation of early hematopoiesis in infection and inflammation. Blood. 2012;119:2991–3002. doi: 10.1182/blood-2011-12-380113. [DOI] [PubMed] [Google Scholar]
- 69.Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA. Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection. Nature. 2010;465:793–797. doi: 10.1038/nature09135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Bernad A, Kopf M, Kulbacki R, Weich N, Koehler G, Gutierrez-Ramos JC. Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. Immunity. 1994;1:725–731. doi: 10.1016/s1074-7613(94)80014-6. [DOI] [PubMed] [Google Scholar]
- 71.Pronk CJ, Veiby OP, Bryder D, Jacobsen SE. Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors. J Exp Med. 2011;208:1563–1570. doi: 10.1084/jem.20110752. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Rebel VI, Hartnett S, Hill GR, Lazo-Kallanian SB, Ferrara JL, Sieff CA. Essential role for the p55 tumor necrosis factor receptor in regulating hematopoiesis at a stem cell level. J Exp Med. 1999;190:1493–1504. doi: 10.1084/jem.190.10.1493. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.McKinstry WJ, Li CL, Rasko JE, Nicola NA, Johnson GR, Metcalf D. Cytokine receptor expression on hematopoietic stem and progenitor cells. Blood. 1997;89:65–71. [PubMed] [Google Scholar]
- 74.Pavan Kumar P, Purbey PK, Sinha CK, Notani D, Limaye A, Jayani RS, Galande S. Phosphorylation of SATB1, a global gene regulator, acts as a molecular switch regulating its transcriptional activity in vivo. Mol Cell. 2006;22:231–243. doi: 10.1016/j.molcel.2006.03.010. [DOI] [PubMed] [Google Scholar]
- 75.Tan JA, Song J, Chen Y, Durrin LK. Phosphorylation-dependent interaction of SATB1 and PIAS1 directs SUMO-regulated caspase cleavage of SATB1. Mol Cell Biol. 2010;30:2823–2836. doi: 10.1128/MCB.01603-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Galande S, Dickinson LA, Mian IS, Sikorska M, Kohwi-Shigematsu T. SATB1 cleavage by caspase 6 disrupts PDZ domain-mediated dimerization, causing detachment from chromatin early in T-cell apoptosis. Mol Cell Biol. 2001;21:5591–5604. doi: 10.1128/MCB.21.16.5591-5604.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Ng SY, Yoshida T, Zhang J, Georgopoulos K. Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells. Immunity. 2009;30:493–507. doi: 10.1016/j.immuni.2009.01.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505:327–334. doi: 10.1038/nature12984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Naik SH, Perie L, Swart E, Gerlach C, van Rooij N, de Boer RJ, Schumacher TN. Diverse and heritable lineage imprinting of early haematopoietic progenitors. Nature. 2013;496:229–232. doi: 10.1038/nature12013. [DOI] [PubMed] [Google Scholar]

